BiTEs have shown potential in treating various types of cancers, including hematological malignancies and solid tumors. The most well-known BiTE, blinatumomab, targets CD19, a protein commonly expressed on B cells, and is approved for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL). Research is ongoing to develop BiTEs targeting other antigens such as HER2, EGFR, and PSMA, which are associated with different types of solid tumors.
